Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study

• Main Authors: Ding K, Chen X, Li Y, Li W, Ye Y, He T, Wang W, Zhang H
• Format: Article
• Language: English
• Published: Dove Medical Press 2021-01-01
• Series: OncoTargets and Therapy
• Subjects: erbb3; gastric cancer; irinotecan; pyrotinib; third-line therapy.
• Online Access: https://www.dovepress.com/gastric-cancer-harboring-an-erbb3-mutation-treated-with-a-pyrotinibnda-peer-reviewed-article-OTT

Kailin Ding,1,* Xian Chen,2,* Yong Li,2 Wenzhu Li,2 Yongsong Ye,3 Tingting He,4 Wenjing Wang,4 Haibo Zhang2 1The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 2Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 3Department of Imaging, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 4OrigiMed, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Haibo ZhangDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, People’s Republic of ChinaTel [phone]Email [e-mail]: Gastric cancer is common, especially in East Asian countries, and is associated with high recurrence and mortality rates. Currently, there is no standard third-line treatment for metastatic gastric cancer. In this report, we present the case of a 69-year-old man with advanced gastric cancer, whose tumor was negative for human epidermal growth factor receptor 2 (HER2) according to immunohistochemical analysis. Next-generation sequencing performed on paraffin sections of the postoperative tumor samples indicated the presence of the ERBB3 V104L mutation. The patient received irinotecan plus pyrotinib as a third-line therapy and achieved a progression-free survival of 7.6 months with a high quality of life. Therefore, the combined administration of irinotecan and pyrotinib may improve the clinical condition of patients with gastric cancer harboring an ERBB3 mutation. Moreover, ERBB3 could be a potential therapeutic target for gastric cancer.Keywords: ERBB3, gastric cancer, irinotecan, pyrotinib, third-line therapy